REGN Regeneron Pharmaceuticals

Q3 2025 10-Q

Filed: Oct 28, 2025Period ending Sep 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Regeneron Pharmaceuticals (REGN) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 28, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $3.75B in Q3 FY2025, up slightly by $33.6M from $3.72B in Q3 FY2024
• Net income $1.46B in Q3 FY2025 vs $1.34B Q3 FY2024; operating margin 27.3% vs 31.7% YoY (operating income $1.03B vs $1.18B)

+3 more insights

Risk Factors

• New risk: FDA Complete Response Letters (CRLs) for odronextamab BLA and EYLEA HD pre-filled syringe delayed approvals in 2025 due to manufacturing inspection issues
• Most updated risk: Biosimilar competition intensifying post-EYLEA US exclusivity expiration May 2024, causing 39-41% decline in US EYLEA sales in 2025

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$3.8B

▲ +0.9% YoY▲ +2.1% QoQ

Net Income

$1.5B

▲ +8.9% YoY▲ +4.9% QoQ

Net Margin

38.9%

▲ +286bp YoY▲ +103bp QoQ

Source: XBRL data from Regeneron Pharmaceuticals Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Regeneron Pharmaceuticals Quarterly Reports

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Regeneron Pharmaceuticals

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.